Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jun 28;19(1):146.
doi: 10.1186/s12883-019-1369-4.

Inflammatory profiling of patients with familial amyloid polyneuropathy

Estefania P Azevedo  1 , Anderson B Guimaraes-Costa  2 , Christianne Bandeira-Melo  3 , Leila Chimelli  4 , Marcia Waddington-Cruz  5 , Elvira M Saraiva  2 , Fernando L Palhano  1 , Debora Foguel  6
Affiliations

Inflammatory profiling of patients with familial amyloid polyneuropathy

Estefania P Azevedo et al. BMC Neurol. .

Abstract

Background: Familial amyloid polyneuropathy (FAP) or ATTRv (amyloid TTR variant) amyloidosis is a fatal hereditary disease characterized by the deposition of amyloid fibrils composed of transthyretin (TTR). The current diagnosis of ATTRv relies on genetic identification of TTR mutations and on Congo Red-positive amyloid deposits, which are absent in most ATTRv patients that are asymptomatic or early symptomatic, supporting the need for novel biomarkers to identify patients in earlier disease phases allowing disease control.

Methods: In an effort to search for new markers for ATTRv, our group searched for nine inflammation markers in ATTRv serum from a cohort of 28 Brazilian ATTRv patients.

Results: We found that the levels of six markers were increased (TNF-α, IL-1β, IL-8, IL-33, IFN-β and IL-10), one had decreased levels (IL-12) and two of them were unchanged (IL-6 and cortisol). Interestingly, asymptomatic patients already presented high levels of IL-33, IL-1β and IL-10, suggesting that inflammation may take place before fibril deposition.

Conclusions: Our findings shed light on a new, previously unidentified aspect of ATTRv, which might help define new criteria for disease management, as well as provide additional understanding of ATTRv aggressiveness.

Keywords: Amyloid; Biomarkers; Cytokines; Familial amyloid polyneuropathy; Transthyretin.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Sera from ATTRv patients exhibit altered immune response. Serum from 28 patients diagnosed positive for ATTRv and 24 age- and sex-matched healthy subjects were collected, and nine different cytokines and immune system associated-molecules were measured: IL-8 (a), IL-33 (b), IL-1β (c), TNF-α (d), IL-10 (e), IL-12 (f), IFN-β (g), IL-6 (h) and cortisol (i). Data were analyzed using unpaired Student’s t test followed by Mann Whitney test. *p < 0.05, **p < 0.01 and ***p < 0.001
Fig. 2
Fig. 2
Sera from asymptomatic and symptomatic ATTRv patients exhibit altered immune response. Serum from 28 patients diagnosed positive for ATTRv and 24 age- and sex-matched healthy subjects were collected, and nine different cytokines and immune system associated-molecules were measured: IL-8 (a), IL-33 (b), IL-1β (c), TNF-α (d), IL-10 (e), IL-12 (f), IFN-β (g), IL-6 (h) and cortisol (i). ATTRv patients were scored by Coutinho index (12) and separated by aggressiveness: FAP 0 = asymptomatic; FAP 1 = mild symptoms; FAP 2–3 = moderate to aggressive symptoms. Data were analyzed using unpaired one-way ANOVA followed by Kruskal-Wallis test. *p < 0.05, **p < 0.01 and ***p < 0.001
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Planté-Bordeneuve V, Said G. Familial amyloid polyneuropathy. Lancet Neurol. 2011;10:1086–1097. doi: 10.1016/S1474-4422(11)70246-0. - DOI - PubMed
    1. Hund E. Familial amyloidotic polyneuropathy: current and emerging treatment options for transthyretin-mediated amyloidosis. Appl Clin Genet. 2012;18:37–41. doi: 10.2147/TACG.S19903. - DOI - PMC - PubMed
    1. Sekijima Y, Wiseman RL, Matteson J, Hammarstrom P, Miller SR, Sawkar AR, Balch WE, Kelly JW. The biological and chemical basis for tissue-selective amyloid disease. Cell. 2005;121:73–85. doi: 10.1016/j.cell.2005.01.018. - DOI - PubMed
    1. Gertz MA, Benson MD, Dyck PJ, Grogan M, Coelho T, Cruz M, Berk JL, Plante-Bordeneuve V, Schmidt HHJ, Merlini G. Diagnosis, prognosis, and therapy of transthyretin amyloidosis. J Am Coll Cardiol. 2015;66:2451–2466. doi: 10.1016/j.jacc.2015.09.075. - DOI - PubMed
    1. Coelho T, Carvalho M, Saraiva MJ, Alves I, Almeida MR, Costa PP. A strikingly benign evolution of ATTRV in an individual found to be a compound heterozygote for two TTR mutations: TTR MET 30 and TTR MET 119. J Rheumatol. 1993;20:179.

Supplementary concepts